Moreover, recent research has constructed a reduction-responsive RNAi nanoplatform that reprograms tumor lipid metabolism by inhibiting the production of free fatty acids (FFAs) and repolarizes TAMs to a pro-inflammatory phenotype, leading to the secretion of tumor-killing cytokines such as TNF-α and IL-12, which achieves combined anti-cancer effects in both xenografts and in situ pancreatic adenocarcinoma (PAC) tumor models [192]. The gene discussed is TNF; the disease is neoplasm.